Stockbridge to head Cardio-Renal permanently
Norman Stockbridge is appointed permanent director of the Center for Drug Evaluation & Research's Division of Cardiovascular and Renal Products. Stockbridge has been serving as acting director since Douglas Throckmorton became CDER deputy director in May 2004 (1"The Pink Sheet" April 19, 2004, p. 4). Stockbridge joined FDA in 1991 as a medical officer and was appointed Cardio-Renal division deputy director in 2002...
You may also be interested in...
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.